An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs 18F MNI 1054 (Primary)
- Indications Unspecified
- Focus Diagnostic use; Pharmacodynamics
- Sponsors Invicro
- 22 May 2019 Status changed from recruiting to completed.
- 29 Apr 2019 New trial record